Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis.

Journal: American heart journal plus : cardiology research and practice
Published Date: Mar 7, 2023

Abstract

BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2i) have been proven to reduce the combined risk of cardiovascular death and hospitalizations in patients with heart failure (HF), irrespective of the presence or absence of diabetes. Despite class 1 and class 2A recommendations for their usage in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) respectively by the American College of Cardiology, their prescription rate has remained low.

Authors

  • Teja Chakrala
    Department of Medicine, University of Florida, Gainesville, FL, United States of America.
  • Roshni O Prakash
    Department of Medicine, University of Florida, Gainesville, FL, United States of America.
  • Justin Kim
    Department of Medicine, University of Florida, Gainesville, FL, United States of America.
  • Hanzhi Gao
    Department of Biostatistics, University of Florida, Gainesville, FL, United States of America.
  • Umar Ghaffar
    Division of Hospital Medicine, University of Florida, Gainesville, FL, United States of America.
  • Jaymin Patel
    Division of Hospital Medicine, University of Florida, Gainesville, FL, United States of America.
  • Alex Parker
    Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States of America.
  • Bhagwan Dass
    Division of Hospital Medicine, University of Florida, Gainesville, FL, United States of America.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals